Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
African nations now lead the world in the rollout of pre-exposure prophylaxis against HIV — in part thanks to social media influencers who promote use of the life-saving drug.
Detection of circulating tumor DNA using MRD-EDGE, a machine-learning-guided single-nucleotide variant and copy-number variant detection platform for signal enrichment, enables monitoring of minimal residual disease and immunotherapy response in settings of low tumor burden.
Genomic and epidemiologic analyses of mpox cases stemming from a recent outbreak in The Democratic Republic of the Congo suggests that a new Clade I lineage is circulating and its spread may be linked to sexual transmission.
In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in patients with relapsed/refractory microsatellite stable colorectal cancer, a tumor type typically unresponsive to immune checkpoint blockade.
A phase 1 trial of PSCA-targeting CAR T cell therapy in patients with PSCA-positive, metastatic castration-resistant prostate cancer demonstrates that the treatment, using a protocol with reduced lymphodepletion, is safe and shows preliminary clinical activity.
This study distinguished age- and metabolism-related gut microbiota signatures and constructed gut microbial age metric using data from a large, prospective cohort. Longitudinal analysis showed that younger microbial age seems to counteract the increased cardiovascular disease risk in metabolically unhealthy older people, indicating an interplay between gut microbiota and host age and metabolism.
We quantified liver, pancreas, heart and kidney fibrosis using MRI T1 mapping in over 40,000 individuals. Using genetic association analyses, we identified a total of 58 loci, 10 of which overlapped across organs. A high burden of fibrosis in three or more organs was associated with an increased risk of mortality.
The largest genome-wide association study of its kind has identified new markers for risk prediction in women of African ancestry — helping to bridge disparities in clinical genomics.
Phase 2 clinical trial results show that retatrutide, a triple agonist of the GIP, GLP-1 and glucagon receptors, results in up to 82% reduction in liver fat.
After early initiation of anti-retroviral therapy in infants infected with HIV-1 in utero, some children sustain undetectable virus levels, despite treatment interruption, and which associated with distinct features of the transmitted virus.
Data from two large longitudinal cohorts in China, in which the participants were clustered into five groups based on their metabolic characteristics, show that a signature of microbiome age modulates the risk of cardiovascular disease in metabolically unhealthy individuals.
An economic evaluation of the E-MOTIVE intervention for postpartum hemorrhage (PPH) compared with usual care in 210,132 women, carried out from a healthcare system perspective, uncovered the cost per case of severe PPH prevented and cost per disability-adjusted life-year averted.
In a single-arm phase 2 trial evaluating intravesical delivery of the oncolytic adenovirus cretostimogene grenadenorepvec with systemic anti-PD-1 in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, the complete response rate at 12 months was 57.1%, meeting the primary endpoint.
In the observational ZERO Childhood Cancer Precision Medicine Program PRecISion Medicine for Children with Cancer (PRISM) trial, children with high-risk cancer were treated with molecular tumor board-recommended therapies, resulting in overall clinical response rates that translated into survival benefit after long-term follow-up.
In a randomized, double-blind phase 3 trial, the anti-α4β7 integrin monoclonal antibody vedolizumab plus standard prophylaxis was superior to placebo plus prophylaxis for prevention of lower gastrointestinal acute graft-versus-host disease in patients following allogeneic hematopoietic stem cell transplantation.